{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:19:13Z","timestamp":1769080753606,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":558,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"China Scholarship Council and University Medical Centre Groningen","award":["202008440347"],"award-info":[{"award-number":["202008440347"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Angiotensin receptor blockers have been shown to reduce heart failure hospitalization and cardiovascular mortality in men and women with heart failure with reduced ejection fraction (HFrEF). It is unknown whether there are differences between men and women in achieved dose and treatment discontinuation due to adverse events of candesartan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a post hoc analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. A total of 3172 men and 1106 women with HFrEF [left ventricular ejection fraction (LVEF) \u2264 40%] in New York Heart Association class II\u2013IV were randomized to candesartan or placebo. Every 2 weeks, patients were up-titrated from 4 or 8, to16, to 32 mg once daily, unless a higher dose was contraindicated or not tolerated. Women were older (66 vs. 64 years), had a higher LVEF (29.9% vs. 28.6%), and had more hypertension (54% vs. 47%) than men. The mean achieved dose of candesartan was 21.5 \u00b1 12.6 mg in men and 20.7 \u00b1 12.9 mg in women (P = 0.19). In both the candesartan and placebo groups, cardiovascular death and heart failure hospitalizations were higher in men and women who achieved lower dose levels. Event rates for achieved dose levels of 0, 4 or 8, 16, and 32 mg candesartan were 20.8, 17.2, 14.0, and 10.1 per 100 person-years in men, respectively, and 23.6, 13.7, 14.0, and 9.1 per 100 person-years in women, respectively. In each of the achieved dose levels, there was no sex difference in the proportion of patients with an event, neither in the candesartan group nor in the placebo group (P-value for all &amp;gt; 0.05). There was no significant interaction between sex and treatment-related discontinuation for hypotension (P = 0.520), an increase in creatinine (P = 0.102), and hyperkalaemia (P = 0.905).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a randomized clinical trial in patients with HFrEF, men and women achieved similar doses of candesartan. Primary event rates and treatment-related discontinuation due to adverse events were also similar between men and women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14715","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T01:40:35Z","timestamp":1712367635000},"page":"1880-1887","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Achieved Dose and Treatment Discontinuation of Candesartan in Men and Women with Chronic Heart Failure: Data from CHARM"],"prefix":"10.1093","volume":"11","author":[{"given":"Hailun","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Hanzeplein 1, 9713 GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Dewan","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadet T.","family":"Santema","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Hanzeplein 1, 9713 GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozine M.","family":"ter Maaten","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Hanzeplein 1, 9713 GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Hanzeplein 1, 9713 GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2026012113133424500_ehf214715-bib-0001","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113133424500_ehf214715-bib-0002","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113133424500_ehf214715-bib-0003","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113133424500_ehf214715-bib-0004","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2026012113133424500_ehf214715-bib-0005","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/ehjcvp\/pvw042","article-title":"Gender differences in the effects of cardiovascular drugs","volume":"3","author":"Tamargo","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012113133424500_ehf214715-bib-0006","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jcph.571","article-title":"Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor","volume":"56","author":"Gan","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2026012113133424500_ehf214715-bib-0007","doi-asserted-by":"publisher","first-page":"311S","DOI":"10.1016\/s0895-7061(97)00391-9","article-title":"The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations","volume":"10","author":"Brunner","year":"1997","journal-title":"Am J Hypertens"},{"key":"2026012113133424500_ehf214715-bib-0008","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/phrs.1997.0202","article-title":"No sex-related pharmacokinetic and pharmacodynamic differences of captopril","volume":"36","author":"Massana","year":"1997","journal-title":"Pharmacol Res"},{"key":"2026012113133424500_ehf214715-bib-0009","first-page":"533","article-title":"Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril","volume":"18","author":"Saenz-Campos","year":"1996","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2026012113133424500_ehf214715-bib-0010","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012113133424500_ehf214715-bib-0011","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa021266","article-title":"Sex-based differences in the effect of digoxin for the treatment of heart failure","volume":"347","author":"Rathore","year":"2002","journal-title":"N Engl J Med"},{"key":"2026012113133424500_ehf214715-bib-0012","first-page":"219","article-title":"Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: A report from the DHSS Hypertension Care Computing Project (DHCCP)","volume":"2","author":"Fletcher","year":"1988","journal-title":"J Hum Hypertens"},{"key":"2026012113133424500_ehf214715-bib-0013","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1053\/cp.1999.v66.103400001","article-title":"Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"66","author":"Luzier","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2026012113133424500_ehf214715-bib-0014","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/clpt.1989.136","article-title":"Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects","volume":"46","author":"Walle","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"2026012113133424500_ehf214715-bib-0015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-3565(25)11136-1","article-title":"Age and gender influence the stereoselective pharmacokinetics of propranolol","volume":"261","author":"Gilmore","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012113133424500_ehf214715-bib-0016","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/00005344-200405000-00018","article-title":"Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers","volume":"43","author":"Zapater","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012113133424500_ehf214715-bib-0017","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0163-7258(97)82002-5","article-title":"Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension","volume":"74","author":"McIntyre","year":"1997","journal-title":"Pharmacol Ther"},{"key":"2026012113133424500_ehf214715-bib-0018","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026012113133424500_ehf214715-bib-0019","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026012113133424500_ehf214715-bib-0020","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s1071-9164(99)90013-1","article-title":"Candesartan in heart failure\u2014Assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Charm-Programme Investigators","volume":"5","author":"Swedberg","year":"1999","journal-title":"J Card Fail"},{"key":"2026012113133424500_ehf214715-bib-0021","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1136\/heartjnl-2021-319229","article-title":"Heart failure medication dosage and survival in women and men seen at outpatient clinics","volume":"107","author":"Bots","year":"2021","journal-title":"Heart"},{"key":"2026012113133424500_ehf214715-bib-0022","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/S0140-6736(19)31792-1","article-title":"Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study","volume":"394","author":"Santema","year":"2019","journal-title":"Lancet"},{"key":"2026012113133424500_ehf214715-bib-0023","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ejhf.2882","article-title":"Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG-HF trial","volume":"25","author":"Cerlinskaite-Bajore","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0024","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"2026012113133424500_ehf214715-bib-0025","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jchf.2020.06.008","article-title":"Efficacy and safety of sacubitril\/valsartan by dose level achieved in the PIONEER-HF trial","volume":"8","author":"Berg","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0026","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0735-1097(02)01970-8","article-title":"Dose of metoprolol CR\/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR\/XL randomized intervention trial in chronic heart failure (MERIT-HF)","volume":"40","author":"Wikstrand","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026012113133424500_ehf214715-bib-0027","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","article-title":"Gender effects in pharmacokinetics and pharmacodynamics","volume":"50","author":"Harris","year":"1995","journal-title":"Drugs"},{"key":"2026012113133424500_ehf214715-bib-0028","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/cpt.1928","article-title":"UGT1A3 and sex are major determinants of telmisartan pharmacokinetics\u2014A comprehensive pharmacogenomic study","volume":"108","author":"Hirvensalo","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026012113133424500_ehf214715-bib-0029","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1124\/dmd.112.046292","article-title":"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers","volume":"41","author":"Cabaleiro","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2026012113133424500_ehf214715-bib-0030","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00005344-200207000-00014","article-title":"Pharmacokinetics of irbesartan are not altered in special populations","volume":"40","author":"Marino","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012113133424500_ehf214715-bib-0031","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"2026012113133424500_ehf214715-bib-0032","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2165\/00003495-199856050-00013","article-title":"Candesartan cilexetil: A review of its use in essential hypertension","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"2026012113133424500_ehf214715-bib-0033","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2165\/00003495-200262080-00016","article-title":"Candesartan cilexetil: An update of its use in essential hypertension","volume":"62","author":"Easthope","year":"2002","journal-title":"Drugs"},{"key":"2026012113133424500_ehf214715-bib-0034","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrd2032","article-title":"Therapeutic implications of the gender-specific aspects of cardiovascular disease","volume":"5","author":"Regitz-Zagrosek","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2026012113133424500_ehf214715-bib-0035","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: The PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0036","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jchf.2023.06.022","article-title":"Clinical inertia among outpatients with heart failure: Application of treatment nonintensification taxonomy to EPIC-HF trial","volume":"11","author":"Swat","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0037","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/ejhf.2255","article-title":"Dosing of losartan in men versus women with heart failure with reduced ejection fraction: The HEAAL trial","volume":"23","author":"Ferreira","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0038","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0039","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012113133424500_ehf214715-bib-0040","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/1880\/64526692\/eschf_11_4_1880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/1880\/64526692\/eschf_11_4_1880.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:15:18Z","timestamp":1769019318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/4\/1880\/8271152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,5]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14715","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"2023-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}